<DOC>
	<DOCNO>NCT00081796</DOCNO>
	<brief_summary>The purpose clinical trial determine RPR109881 well treatment capecitabine ( Xeloda ) advance breast cancer patient longer benefit docetaxel and/or paclitaxel .</brief_summary>
	<brief_title>Breast Cancer Trial RPR109881 Versus Capecitabine Male Female Patients With Advanced Breast Cancer</brief_title>
	<detailed_description>All patient trial receive either investigational drug capecitabine , chemotherapy drug already approve treat disease . These drug prevent tumor cell divide , may stop grow die . The investigational drug clinical trial chemotherapy drug give vein every three week . Patients receive capecitabine receive drug mouth 14 day , every 21 day .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Eligibility Criteria In order eligible trial must : Have diagnosis breast cancer metastatic ( mean cancer spread beyond original location ) recurrence cancer original location remove surgery . Have receive previous treatment anthracyclines ( e.g. , adriamycin , Doxorubicin ) taxanes ( e.g. , paclitaxel , docetaxel , Taxol® , Taxotere® ) breast cancer doctor determine treatment longer benefit . Be least 18 year age . Not take treatment cancer time enter trial . Not pregnant . Additionally , criterion study entry doctor participate study need review detail clinical assessment may need perform ( e.g. , lab test , CT scan ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Metastatic Breast Cancer</keyword>
</DOC>